Under normal conditions, stem cells bearing TP53 mutations are no more likely to replace their neighboring wild type stem cells within the crypt base, while APC and KRAS mutations, which are more frequently encountered in sporadic CRC (75), offer a clear survival/growth advantage. The gene discussed is APC; the disease is colorectal carcinoma.